Patents Assigned to Japan as represented by General Director of Agency of National Center for Child Health and Development
  • Patent number: 7172867
    Abstract: Differential expression of genes whose expression is different in the activated eosinophils of atopic dermatitis patients was measured by comparative analysis using a gene chip. As a result, the TR3 and TINUR genes, whose expression is significantly elevated in activated eosinophils, were successfully identified. The present inventors discovered that these genes can be used to test for allergic disease and to screen candidate compounds for therapeutic agents for allergic disease.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: February 6, 2007
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yuji Sugita, Hirohisa Saito
  • Patent number: 7148011
    Abstract: The differential display method was used to search for a gene whose expression level in eosinophils collected from patients with atopic dermatitis differs in the exacerbation stage and in the remission stage. As a result, gene “2090-05” showing a significant increase in expression in eosinophils of patients in the remission stage was isolated. This gene is usable in testing for an allergic disease and screening for a candidate compound for a therapeutic agent therefor an allergic disease.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: December 12, 2006
    Assignees: Japan as represented by General Director of Agency of National Center for Child Health and Development, Eisai Co., Ltd., Genox Research, Inc.
    Inventors: Yuji Sugita, Ryoichi Hashida, Kaoru Ogawa, Tomoko Fujishima, Takeshi Nagasu, Gozoh Tsujimoto, Eiki Takahashi
  • Patent number: 7115373
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: October 3, 2006
    Assignees: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center For Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Publication number: 20040214192
    Abstract: Genes whose expression differ between that in eosinophils collected from atopic dermatitis patients of the exabartation stage and those of the remission stage were searched via a differential display method. As a result, NOR-1 (MINOR) gene was successfully identified whose expression significantly increased in eosinophils of patients in the remission stage, a stage associated with a decrease of eosinophils. The present inventors discovered that the gene can be successfully employed in testing for allergic diseases and screening for candidate compounds for therapeutic agents.
    Type: Application
    Filed: June 27, 2003
    Publication date: October 28, 2004
    Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Ryoichi Hashida, Shinji Kagaya, Yoshihiro Yayoi, Yuji Sugita, Hirohisa Saito
  • Publication number: 20030224423
    Abstract: B1799 gene, whose expression level increases significantly in the patient group, was successfully identified by screening for a gene which shows difference in expression in blood collected from multiple healthy subjects and patients of allergic diseases employing the differential display method. The gene expression level is specifically high in T cells and increased due to T cell activation. This gene can be used in testing for allergic diseases and also in screening for therapeutic agents for allergic diseases.
    Type: Application
    Filed: April 3, 2003
    Publication date: December 4, 2003
    Applicants: Genox Research, Inc., Japan as Represented by General Director of Agency of National Center for Child Health & Development
    Inventors: Yoshiko Matsumoto, Yukiho Imai, Nei Yoshida, Tadahiro Oshida, Yuji Sugita, Hirohisa Saito
  • Publication number: 20030219796
    Abstract: The SOCS3 gene has been identified as a gene whose expression level in T cells of patients with an atopic disorder is significantly higher than that of the normal healthy subjects. The present inventors found that this gene can be used in testing for allergic diseases and in screening for therapeutic agents. The present invention enables screening for compounds useful in the treatment of allergic diseases.
    Type: Application
    Filed: February 27, 2003
    Publication date: November 27, 2003
    Applicants: Genox Research, Inc., Japan as represented by general director of agency of National Center for Child Health & Development
    Inventors: Naoko Nagata, Tadahiro Oshida, Yuji Sugita, Masato Kubo, Hirohisa Saito